WILMINGTON, Del.--(BUSINESS WIRE)--NiKang Therapeutics® Inc. (“NiKang”) is a clinical stage biotech company focused on developing innovative small molecule oncology medicines to bring transformative therapies to patients in need. The company announced today the unveiling of NKT3964 at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (“Triple Meeting”) during a Poster Spotlight Session.

Del.威尔明顿（商业新闻短讯）--NiKang Therapeutics®Inc.（“NiKang”）是一家临床阶段的生物技术公司，专注于开发创新的小分子肿瘤药物，为有需要的患者带来变革性治疗。该公司今天在EORTC-NCI-AACR分子靶标和癌症治疗研讨会（“三重会议”）上，在海报聚光灯会议上宣布推出NKT3964。

The conference is being held October 23-25, 2024, in Barcelona, Spain. NKT3964 is a first-in-class, orally bioavailable small molecule CDK2 degrader that selectively degrades CDK2, demonstrating high specificity over CDK1 and other CDK family members. Its high potency and unique mechanism of action result in sustained inhibition of CDK2 pathway without causing cyclin E accumulation.

会议将于2024年10月23日至25日在西班牙巴塞罗那举行。NKT3964是一种一流的口服生物可利用小分子CDK2降解剂，可选择性降解CDK2，比CDK1和其他CDK家族成员具有高度特异性。其高效力和独特的作用机制导致持续抑制CDK2途径而不引起细胞周期蛋白E积累。

NKT3964 is designed to treat patients with aberrant CDK2/cyclin E pathway activation, including those with ovarian, endometrial, gastric and HR+HER2- breast cancers..

NKT3964旨在治疗CDK2/细胞周期蛋白E通路异常激活的患者，包括卵巢癌，子宫内膜癌，胃癌和HR+HER2乳腺癌患者。。

NiKang has initiated a phase 1, open-label, dose escalation study of NKT3964 as a single agent. This first-in-human study (NCT06586957) is designed to evaluate the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity to determine the preliminary recommended dose for expansion of NKT3964 in adults with advanced or metastatic solid tumors..

尼康已经启动了NKT3964作为单一药物的第一阶段开放标签剂量递增研究。这项首次人体研究（NCT06586957）旨在评估安全性，耐受性，药代动力学和初步抗肿瘤活性，以确定晚期或转移性实体瘤成人NKT3964扩增的初步推荐剂量。。

“We are excited to share the discovery of NKT3964, a first-in-class oral CDK2 degrader at this year’s Triple Meeting,” said Zhenhai Gao, Ph.D., co-founder, president, and CEO of NiKang. “This is the second of three programs targeting the cell cycle (CDK2 inhibitor NKT3447, CDK2 degrader NKT3964, and a CDK2/4 selective dual degrader) that we have advanced to the clinic.

尼康联合创始人、总裁兼首席执行官高振海博士表示：“我们很高兴在今年的三重会议上分享NKT3964的发现，这是一种一流的口服CDK2降解剂。”。“这是我们已经进入临床的针对细胞周期的三个程序（CDK2抑制剂NKT3447，CDK2降解剂NKT3964和CDK2/4选择性双重降解剂）中的第二个。

We believe CDK2 plays a critical role in driving tumor growth. Recent clinical data presented at ESMO further validates CDK2 as a key oncology target. We are developing a cutting-edge portfolio of CDK2 and CDK2/4 degraders that can achieve sustained CDK pathway inhibition while avoiding paradoxical cyclin E increase.

我们认为CDK2在驱动肿瘤生长中起着关键作用。ESMO上提供的最新临床数据进一步验证了CDK2是关键的肿瘤学靶点。我们正在开发CDK2和CDK2/4降解剂的前沿组合，可以实现持续的CDK途径抑制，同时避免矛盾的细胞周期蛋白E增加。

Our multi-pronged approach allows us to thoroughly and deeply interrogate this pathway. We look forward to exploring NKT3964’s potential in treating patients with advanced or metastatic solid tumors.”.

我们的多管齐下的方法使我们能够彻底和深入地审问这条途径。我们期待着探索NKT3964在治疗晚期或转移性实体瘤患者中的潜力。”。

Poster Presentation Details:

海报展示细节：

Title:

标题：

Discovery of NKT3964: a first-in-class, highly potent and selective, orally bioavailable CDK2 PROTAC degrader for cancer therapy

NKT3964的发现：用于癌症治疗的一流，高效和选择性，口服生物可利用的CDK2-PROTAC降解剂

Presenter:

Jianlin Geng, Ph.D.

耿建林博士。

Abstract Number:

摘要编号：

PB002

PB002

Session:

会议：

Posters in the Spotlight

聚光灯下的海报

Date/Time:

日期/时间：

2:00 p.m.-2:40 p.m. CEST on October 24, 2024

2024年10月24日美国东部标准时间下午2:00至2:40

About NKT3964

关于NKT3964

NKT3964 is a first-in-class, highly potent and selective, orally bioavailable CDK2 PROTAC degrader, causing prolonged CDK2 pathway inhibition without cyclin E accumulation. It has the potential to maximally inhibit the CDK2 pathway, fully harnessing the therapeutic benefits of CDK2 inhibition. NKT3964 is currently under evaluation in a Phase 1 clinical study in advanced or metastatic solid tumors as a single agent (NCT06586957)..

NKT3964是一流的，高效和选择性的，口服生物可利用的CDK2 PROTAC降解剂，可延长CDK2途径的抑制作用，而不会积累细胞周期蛋白E。它有可能最大程度地抑制CDK2途径，充分利用CDK2抑制的治疗益处。NKT3964目前正在作为单一药物在晚期或转移性实体瘤的1期临床研究中进行评估（NCT06586957）。。

About NiKang Therapeutics

关于NiKang Therapeutics

NiKang Therapeutics is a clinical-stage biotech company focused on discovering and developing innovative small molecule oncology medicines to bring transformative therapies to patients in need. Our target selection is driven by deep insight into disease biology and molecular pathways. Our discovery approach is informed by target structure biology and capitalizes on structure-based drug design.

NiKang Therapeutics是一家临床阶段的生物技术公司，专注于发现和开发创新的小分子肿瘤药物，为有需要的患者带来变革性疗法。我们的目标选择是由对疾病生物学和分子途径的深入了解驱动的。我们的发现方法由目标结构生物学提供信息，并利用基于结构的药物设计。

The successful implementation of our strategy enables us to rapidly and efficiently discover and advance proprietary drug candidates with the most desirable pharmacological features into clinical studies. We have successfully advanced three programs into clinical trials, including NKT2152 (HIF2α), NKT3447 (CDK2), and NKT3964 (CDK2)..

我们策略的成功实施使我们能够快速有效地发现并将具有最理想药理学特征的专有候选药物推进临床研究。我们已经成功地将三个项目推进临床试验，包括NKT2152（HIF2α），NKT3447（CDK2）和NKT3964（CDK2）。。

For more information, please visit http://www.nikangtx.com

For more information, please visit http://www.nikangtx.com